相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。8O89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors
D Giesen et al.
ANNALS OF ONCOLOGY (2019)
Targeting Tumor Microenvironment for Cancer Therapy
Catarina Roma-Rodrigues et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation
Olga Vasiljeva et al.
BIOLOGICAL CHEMISTRY (2019)
CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A coiled-coil masking domain for selective activation of therapeutic antibodies
Vivian H. Trang et al.
NATURE BIOTECHNOLOGY (2019)
Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy
Yun-Chi Lu et al.
PLOS BIOLOGY (2019)
Current trends and challenges in cancer management and therapy using designer nanomaterials
P. N. Navya et al.
NANO CONVERGENCE (2019)
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Chien-Chun Steven Pai et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Alexander N. Shoushtari et al.
JAMA ONCOLOGY (2018)
436PPreliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
R Plummer et al.
ANNALS OF ONCOLOGY (2018)
BRD4 and Cancer: going beyond transcriptional regulation
Benedetta Donati et al.
MOLECULAR CANCER (2018)
Masked Chimeric Antigen Receptor for Tumor-Specific Activation
Xiaolu Han et al.
MOLECULAR THERAPY (2017)
Coagulation factor and protease pathways in thrombosis and cardiovascular disease
Hugo ten Cate et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains
I-Ju Chen et al.
SCIENTIFIC REPORTS (2017)
Matrix metalloproteinases - From the cleavage data to the prediction tools and beyond
Piotr Cieplak et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
Tumor-targeting peptides from combinatorial libraries
Ruiwu Liu et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy
Yun Yang et al.
MABS (2016)
Matrix Metalloproteinases in Non-Neoplastic Disorders
Akinori Tokito et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Phatsapong Yingchoncharoen et al.
PHARMACOLOGICAL REVIEWS (2016)
Imaging Active Urokinase Plasminogen Activator in Prostate Cancer
Aaron M. LeBeau et al.
CANCER RESEARCH (2015)
Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency
Yun Yang et al.
MABS (2015)
Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation
Shimobi C. Onuoha et al.
ARTHRITIS & RHEUMATOLOGY (2015)
How it all starts: Initiation of the clotting cascade
Stephanie A. Smith et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2015)
Probody therapeutics for targeting antibodies to diseased tissue
Krishna R. Polu et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Pericellular proteolysis in cancer
Lisa Sevenich et al.
GENES & DEVELOPMENT (2014)
Zymography methods for visualizing hydrolytic enzymes
Jennifer Vandooren et al.
NATURE METHODS (2013)
Imaging a functional tumorigenic biomarker in the transformed epithelium
Aaron M. LeBeau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Luc R. Desnoyers et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
pH-sensitive drug-delivery systems for tumor targeting
Xi He et al.
THERAPEUTIC DELIVERY (2013)
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases
Oran Erster et al.
JOURNAL OF CONTROLLED RELEASE (2012)
New approaches for dissecting protease functions to improve probe development and drug discovery
Edgar Deu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing
Silke Metz et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2012)
Prodrugs for improving tumor targetability and efficiency
Rubi Mahato et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Emerging principles in protease-based drug discovery
Marcin Drag et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
Ralf Lutterbuese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Design and development of masked therapeutic antibodies to limit off-target effects Application to anti-EGFR antibodies
Joshua M. Donaldson et al.
CANCER BIOLOGY & THERAPY (2009)
Proligands with protease-regulated binding activity identified from cell-displayed prodomain libraries
Jerry M. Thomas et al.
PROTEIN SCIENCE (2009)
Targeting proteases: successes, failures and future prospects
Boris Turk
NATURE REVIEWS DRUG DISCOVERY (2006)